Ignite Creation Date:
2024-05-06 @ 3:39 AM
Last Modification Date:
2024-10-26 @ 11:36 AM
Study NCT ID:
NCT02333253
Status:
COMPLETED
Last Update Posted:
2016-01-27
First Post:
2015-01-02
Brief Title:
Delayed Start Versus Conventional Antagonist Protocol in Poor Responders Pretreated by Estradiol in Luteal Phase
Sponsor:
Cairo University
Organization:
Cairo University
Study Overview
Official Title:
Delayed Start vs Conventional Antagonist Protocol in Poor Responders Pretreated by Estradiol in Luteal Phase
Status:
COMPLETED
Status Verified Date:
2016-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
40 patients attending IVF center during 2013 2014 were fulfilling criteria of poor response and they failed to go through OPU as they gave 3 mature follicles on a dose of 300U GN or more All patients were revised for history examinations and investigations including age type and duration of infertility day 3 FSH Day 3 E2 AMH AFC
Detailed Description:
40 patients attending IVF center during 2013 2014 were fulfilling criteria of poor response and they failed to go through OPU as they gave 3 mature follicles on a dose of 300U GN or more All patients were revised for history examinations and investigations including age type and duration of infertility day 3 FSH Day 3 E2 AMH AFC All patients were 35 years old ore more We exclude patient 44ys AMH 03ngmlFSH 13 also patients of DM endometriosis general disease were excluded any local uterine anomalies were excluded
All patients received OCP for one cycle Then all had taken estradiol tablet 2 mg for one week prior to menses of the test cycle from Day 21 to day 28 Then we divide them into 2 groups US were done to exclude any cyst or follicle 10mm First group received 300 U r FSH 150 U urinary GN from day 2 till day of HCGdose adjusted according to the response then 025 cetrotide Sc was added on when leading follicle reach 12 mm HCG was given only if we have at least 3 mature follicles 14 mm and the leading one 17mm then OPU done after 36 hrs of HCG oocytes were denuded and fertilized by ICSI to avoid low fertilization rate by conventional IVFembryo transfer were done on day 3 when we have at least one embryo GI other wise cancelled ET then cyclogest 800mg were given intravaginal for 14 days then quantitative BHCG done and considered positive if 5miuML 28 day after ET TVS was done to confirm ongoing pregnancy by visualization of IU sac
Second group were received cetrotide 025 mg sc alone from day 2 to day 8then we initiate GN therapy by same initial GN dose 300FSH150U urinary GNsame adjustment of dose were done and antagonist restarted when DF 12mm till day of HCG HCGOPU ET were done by same method and under same criteria luteal support and follow were the same
All patients received OCP for one cycle Then all had taken estradiol tablet 2 mg for one week prior to menses of the test cycle from Day 21 to day 28 Then we divide them into 2 groups US were done to exclude any cyst or follicle 10mm First group received 300 U r FSH 150 U urinary GN from day 2 till day of HCGdose adjusted according to the response then 025 cetrotide Sc was added on when leading follicle reach 12 mm HCG was given only if we have at least 3 mature follicles 14 mm and the leading one 17mm then OPU done after 36 hrs of HCG oocytes were denuded and fertilized by ICSI to avoid low fertilization rate by conventional IVFembryo transfer were done on day 3 when we have at least one embryo GI other wise cancelled ET then cyclogest 800mg were given intravaginal for 14 days then quantitative BHCG done and considered positive if 5miuML 28 day after ET TVS was done to confirm ongoing pregnancy by visualization of IU sac
Second group were received cetrotide 025 mg sc alone from day 2 to day 8then we initiate GN therapy by same initial GN dose 300FSH150U urinary GNsame adjustment of dose were done and antagonist restarted when DF 12mm till day of HCG HCGOPU ET were done by same method and under same criteria luteal support and follow were the same
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None